The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT).
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: LILLY, SA
- Phase: III
- Execution start: 13/07/2020
- End of execution: 30/10/2024
- IP: MARTIN LOPEZ DE LA TORRE CASARES